BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 20005756)

  • 1. Combined pharmacophore and structure-guided studies to identify diverse HSP90 inhibitors.
    Sanam R; Tajne S; Gundla R; Vadivelan S; Machiraju PK; Dayam R; Narasu L; Jagarlapudi S; Neamati N
    J Mol Graph Model; 2010 Feb; 28(6):472-7. PubMed ID: 20005756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
    Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF
    J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of benzisoxazoles as potent inhibitors of chaperone heat shock protein 90.
    Gopalsamy A; Shi M; Golas J; Vogan E; Jacob J; Johnson M; Lee F; Nilakantan R; Petersen R; Svenson K; Chopra R; Tam MS; Wen Y; Ellingboe J; Arndt K; Boschelli F
    J Med Chem; 2008 Feb; 51(3):373-5. PubMed ID: 18197612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacophore-based virtual screening and docking studies on Hsp90 inhibitors.
    Saxena S; Chaudhaery SS; Varshney K; Saxena AK
    SAR QSAR Environ Res; 2010 Jul; 21(5-6):445-62. PubMed ID: 20818581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure based design of heat shock protein 90 inhibitors acting as anticancer agents.
    Doddareddy MR; Thorat DA; Seo SH; Hong TJ; Cho YS; Hahn JS; Pae AN
    Bioorg Med Chem; 2011 Mar; 19(5):1714-20. PubMed ID: 21306907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone.
    Kung PP; Funk L; Meng J; Collins M; Zhou JZ; Johnson MC; Ekker A; Wang J; Mehta P; Yin MJ; Rodgers C; Davies JF; Bayman E; Smeal T; Maegley KA; Gehring MR
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6273-8. PubMed ID: 18929486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
    Schwock J; Pham NA; Cao MP; Hedley DW
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tricyclic series of heat shock protein 90 (Hsp90) inhibitors part I: discovery of tricyclic imidazo[4,5-c]pyridines as potent inhibitors of the Hsp90 molecular chaperone.
    Vallée F; Carrez C; Pilorge F; Dupuy A; Parent A; Bertin L; Thompson F; Ferrari P; Fassy F; Lamberton A; Thomas A; Arrebola R; Guerif S; Rohaut A; Certal V; Ruxer JM; Gouyon T; Delorme C; Jouanen A; Dumas J; Grépin C; Combeau C; Goulaouic H; Dereu N; Mikol V; Mailliet P; Minoux H
    J Med Chem; 2011 Oct; 54(20):7206-19. PubMed ID: 21972823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
    Ge J; Normant E; Porter JR; Ali JA; Dembski MS; Gao Y; Georges AT; Grenier L; Pak RH; Patterson J; Sydor JR; Tibbitts TT; Tong JK; Adams J; Palombella VJ
    J Med Chem; 2006 Jul; 49(15):4606-15. PubMed ID: 16854066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of benzamide tetrahydro-4H-carbazol-4-ones as novel small molecule inhibitors of Hsp90.
    Barta TE; Veal JM; Rice JW; Partridge JM; Fadden RP; Ma W; Jenks M; Geng L; Hanson GJ; Huang KH; Barabasz AF; Foley BE; Otto J; Hall SE
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3517-21. PubMed ID: 18511277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel class of Hsp90 inhibitors isolated by structure-based virtual screening.
    Park H; Kim YJ; Hahn JS
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6345-9. PubMed ID: 17869098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors.
    Gyurkocza B; Plescia J; Raskett CM; Garlick DS; Lowry PA; Carter BZ; Andreeff M; Meli M; Colombo G; Altieri DC
    J Natl Cancer Inst; 2006 Aug; 98(15):1068-77. PubMed ID: 16882944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the chemical diversity of an hsp90 database.
    Audisio D; Messaoudi S; Ijjaali I; Dubus E; Petitet F; Peyrat JF; Brion JD; Alami M
    Eur J Med Chem; 2010 May; 45(5):2000-9. PubMed ID: 20170986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling.
    Al Shaer L; Walsby E; Gilkes A; Tonks A; Walsh V; Mills K; Burnett A; Rowntree C
    Br J Haematol; 2008 May; 141(4):483-93. PubMed ID: 18373709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity.
    Rowlands MG; Newbatt YM; Prodromou C; Pearl LH; Workman P; Aherne W
    Anal Biochem; 2004 Apr; 327(2):176-83. PubMed ID: 15051534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular modelling and docking studies on heat shock protein 90 (Hsp90) inhibitors.
    Saxena AK; Saxena S; Chaudhaery SS
    SAR QSAR Environ Res; 2010 Jan; 21(1):1-20. PubMed ID: 20373211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lead generation of heat shock protein 90 inhibitors by a combination of fragment-based approach, virtual screening, and structure-based drug design.
    Miura T; Fukami TA; Hasegawa K; Ono N; Suda A; Shindo H; Yoon DO; Kim SJ; Na YJ; Aoki Y; Shimma N; Tsukuda T; Shiratori Y
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5778-83. PubMed ID: 21875802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors.
    Zaarur N; Gabai VL; Porco JA; Calderwood S; Sherman MY
    Cancer Res; 2006 Feb; 66(3):1783-91. PubMed ID: 16452239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90.
    Llauger L; He H; Kim J; Aguirre J; Rosen N; Peters U; Davies P; Chiosis G
    J Med Chem; 2005 Apr; 48(8):2892-905. PubMed ID: 15828828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular characterization of macbecin as an Hsp90 inhibitor.
    Martin CJ; Gaisser S; Challis IR; Carletti I; Wilkinson B; Gregory M; Prodromou C; Roe SM; Pearl LH; Boyd SM; Zhang MQ
    J Med Chem; 2008 May; 51(9):2853-7. PubMed ID: 18357975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.